

Notice of Allowability	Application No.	Applicant(s)	
	09/970,515	BONNY, CHRISTOPHE	
	Examiner	Art Unit	
	David J Steadman	1652	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTO-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. This communication is responsive to the amendment filed January 29, 2004.
2. The allowed claim(s) is/are 1,20 and 23-33.
3. The drawings filed on 03 October 2001 are accepted by the Examiner.
4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some* c) None of the:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) hereto or 2) to Paper No./Mail Date _____.
 - (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. Notice of References Cited (PTO-892)
2. Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. Information Disclosure Statements (PTO-1449 or PTO/SB/08),
Paper No./Mail Date _____
4. Examiner's Comment Regarding Requirement for Deposit
of Biological Material
5. Notice of Informal Patent Application (PTO-152)
6. Interview Summary (PTO-413),
Paper No./Mail Date _____.
7. Examiner's Amendment/Comment
8. Examiner's Statement of Reasons for Allowance
9. Other _____.

DETAILED ACTION

Status of the Application

- [1] Claims 1, 20, and 23-33 are pending in the application.
- [2] Applicants' amendment to the claims, filed January 29, 2004, is acknowledged. This listing of the claims replaces all previous listings and versions of the claims.
- [3] Applicants' amendment to the specification, filed January 29, 2004, is acknowledged. It is noted that the amendment to page 1 of the specification states, "USSN 09/503,954, filed February 14, 2000, now issued as United States Patent No. 6,108,820", however, the correct US Patent number issuing from application 09/503,954 is 6,610,820. The incorrect patent number, i.e., "6,108,820", has been replaced with "6,610,820" by examiner's amendment in accordance with MPEP 1302.04.
- [4] A terminal disclaimer was filed in this application on January 29, 2004. The terminal disclaimer filed January 29, 2004 cites a US Patent number that does not correspond to the issued application cited in the double patenting rejection as set forth in items [16]-[18] of the Office action mailed July 29, 2003. In a telephone conversation with applicant's representative on March 26, 2004, applicant's representative was made aware of this typographical error. A subsequent terminal disclaimer was filed on March 29, 2004. The terminal disclaimer filed on March 29, 2004, disclaiming the terminal portion of any patent granted on this application which would extend beyond the expiration date of US Patent 6,610,820 has been reviewed and is accepted. The terminal disclaimer has been recorded.

[5] Applicants' arguments in the amendment filed January 29, 2004 have been fully considered and are deemed to be persuasive to overcome the rejections previously applied.

Oath/Declaration

[6] The oath or declaration is defective. A new oath or declaration in compliance with 37 CFR 1.67(a) identifying this application by application number and filing date is required. See MPEP §§ 602.01 and 602.02. The oath or declaration is defective because: It does not identify the city and either state or foreign country of residence of each inventor. The residence information may be provided on either on an application data sheet or supplemental oath or declaration.

[7] Applicant is now required to submit a substitute declaration or oath to correct the deficiencies set forth above. The substitute oath or declaration must be filed within the THREE MONTH shortened statutory period set for reply in the "Notice of Allowability" (PTO-37). Extensions of time may NOT be obtained under the provisions of 37 CFR 1.136. Failure to timely file the substitute declaration (or oath) will result in **ABANDONMENT** of the application. The transmittal letter accompanying the declaration (or oath) should indicate the date of the "Notice of Allowance" (PTOL-85) and the application number in the upper right hand corner.


Reasons for Allowance

[8] The following is an Examiner's statement of reasons for allowance. The examiner has found no teaching or suggestion in the prior art directed to a peptide having the sequences of SEQ ID NO:4 or 15. Therefore, claims 1, 20, and 23-33, directed to peptides comprising or consisting of SEQ ID NO:4 or 15 and having the ability to inhibit JNK phosphorylation of c-Jun, ATF2, and Elk1, are allowable over the prior art of record.

[9] Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David Steadman, whose telephone number is (571) 272-0942. The Examiner can normally be reached Monday-Friday from 7:30 am to 4:00 pm. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Ponnathapura Achutamurthy, can be reached at (571) 272-0928. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Art Unit receptionist whose telephone number is (703) 308-0196.

David J. Steadman, Ph.D.
Patent Examiner
Art Unit 1652

 04-13-04